Tweets by IDWeek 2023

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

271 Views

138. COVID-19: Research: Friday, 12:15 - 1:30 p.m.

Poster Session: COVID-19: Research

(1354) Safety of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of COVID-19: 15-Month Final Analysis of the PROVENT Phase 3 Study

Friday, October 13, 2023

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Co-Author(s)

ML

Myron J. Levin, MD

Professor
University of Colorado Denver School of Medicine
Aurora, Colorado, United States
AU

Andrew Ustianowski, MD, PhD

North Manchester General Hospital
Manchester, England, United Kingdom
SD

Stéphane De Wit, MD

CHU St-Pierre
Brussels, Brussels Hoofdstedelijk Gewest, Belgium
RB

Rohini Beavon, PhD

AstraZeneca
Cambridge, England, United Kingdom
JT

Jesse Thissen, MSc

AstraZeneca
Cambridge, England, United Kingdom
SS

Seth Seegobin, PhD

AstraZeneca
Cambridge, England, United Kingdom
Katie Streicher, PhD (she/her/hers)

Head of Translational Medicine, Vaccines and Immune Therapies
AstraZeneca
Gaithersburg, Maryland, United States
AK

Alexandre Kiazand, MD

AstraZeneca
Gaithersburg, Maryland, United States

Mark T. Esser, PhD

Phylogenetic and alpha toxin variant analyses of Staphylococcus aureus strains isolated from patient
AstraZeneca
Gaithersburg, Maryland, United States